NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential
Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric
oxide (NO). Impaired bioavailability and/or responsiveness to endogenous NO has been …
oxide (NO). Impaired bioavailability and/or responsiveness to endogenous NO has been …
NO‐and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle
Soluble guanylyl cyclase (sGC) is the only proven receptor for the ubiquitous biological
messenger nitric oxide (NO) and is intimately involved in many signal transduction …
messenger nitric oxide (NO) and is intimately involved in many signal transduction …
NO-independent, haem-dependent soluble guanylate cyclase stimulators
The nitric oxide (NO) signalling pathway is altered in cardiovascular diseases, including
systemic and pulmonary hypertension, stroke, and atherosclerosis. The vasodilatory …
systemic and pulmonary hypertension, stroke, and atherosclerosis. The vasodilatory …
[HTML][HTML] From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
P Sandner - Biological chemistry, 2018 - degruyter.com
Nitric oxide (NO) signaling represents one of the major regulatory pathways for
cardiovascular function. After the discovery of NO, awarded with the Nobel Prize in 1998 …
cardiovascular function. After the discovery of NO, awarded with the Nobel Prize in 1998 …
Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications
B Nossaman, E Pankey… - Critical care research and …, 2012 - Wiley Online Library
The heme‐protein soluble guanylyl cyclase (sGC) is the intracellular receptor for nitric oxide
(NO). sGC is a heterodimeric enzyme with α and β subunits and contains a heme moiety …
(NO). sGC is a heterodimeric enzyme with α and β subunits and contains a heme moiety …
Soluble guanylate cyclase stimulators and activators
P Sandner, DP Zimmer, GT Milne, M Follmann… - Reactive oxygen …, 2021 - Springer
Abstract When Furchgott, Murad, and Ignarro were honored with the Nobel prize for the
identification of nitric oxide (NO) in 1998, the therapeutic implications of this discovery could …
identification of nitric oxide (NO) in 1998, the therapeutic implications of this discovery could …
The chemistry and biology of soluble guanylate cyclase stimulators and activators
M Follmann, N Griebenow, MG Hahn… - Angewandte Chemie …, 2013 - Wiley Online Library
The vasodilatory properties of nitric oxide (NO) have been utilized in pharmacotherapy for
more than 130 years. Still today, NO‐donor drugs are important in the management of …
more than 130 years. Still today, NO‐donor drugs are important in the management of …
NO-and haem-independent soluble guanylate cyclase activators
Oxidative stress, a risk factor for several cardiovascular disorders, interferes with the
NO/sGC/cGMP signalling pathway through scavenging of NO and formation of the strong …
NO/sGC/cGMP signalling pathway through scavenging of NO and formation of the strong …
Regulation of nitric oxide-sensitive guanylyl cyclase
A Friebe, D Koesling - Circulation research, 2003 - Am Heart Assoc
In this review, we outline the current knowledge on the regulation of nitric oxide (NO)-
sensitive guanylyl cyclase (GC). Besides NO, the physiological activator that binds to the …
sensitive guanylyl cyclase (GC). Besides NO, the physiological activator that binds to the …
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease
Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxide (NO) signaling pathway, is
attracting rapidly growing interest as a therapeutic target in cardiopulmonary disease, with …
attracting rapidly growing interest as a therapeutic target in cardiopulmonary disease, with …